This post was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. Sail-away It’s January on a ship in the South Pacific. Instead of enjoying hula and coconuts, I’m struggling to

This post was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. Those of us in biotech tend to focus our attention on drug discovery and development, but it is also

This post was written by JC Gutierrez-Ramos, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC. When I was a graduate student, I listened to the famous developmental biologist Lewis Wolpert say, “It is not birth

Biotech has been one of the hottest sectors in the venture capital asset class over the past few years. Strong IPO and M&A markets have put wind in the sails of the space since 2012, and robust investment activity has

After five very strong years, biotech as a sector has struggled to catalyze positive investor sentiment so far for the past twelve months. In a disastrous start to the year, the NASDAQ Biotech Index shed 30% in just the first

This post was written by Jason Gardner, Atlas EIR and CEO of Magenta Therapeutics, as part of the From The Trenches feature of LifeSciVC. A new type of medicine was approved in Europe at the end of May that culminated

This blog was written by Ron Renaud, CEO of RaNA Therapeutics, as part of the From The Trenches feature of LifeSciVC. About three weeks ago, I attended a dinner organized by a good friend and former sell-side competitor, Dr. Yaron

This blog was written by Samantha Truex, former CBO of Padlock Therapeutics, as part of the From The Trenches feature of LifeSciVC. I grew up in a setting where “continuous improvement” and “total quality management” were household terms, as unusual

With the big cancer confab ASCO 2016 fading into memory, R&D teams everywhere are getting back to work on their cancer programs – and across the industry many of them will be doing the same work, on the same targets,

This blog was written by Jeb Keiper, CBO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. Unsurprisingly, I had not given that much thought to the parent entity of my new employer when I

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. As a controlled experiment, try placing a tape recorder, rotary phone or record album in front of an 8

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Startup life can be grueling.  It’s an especially gratifying feeling when your data and your investors signal that it’s